Clinical trial
A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
NCT03919162 is registered in ClinicalTrials.gov with Vivoryon Therapeutics N.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)
- Lead sponsor
- Vivoryon Therapeutics N.V.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- November 15, 2021
- Completion date
- August 12, 2024
- Enrollment
- 112 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.